Tyra Biosciences, Inc. financial data

Symbol
TYRA on Nasdaq
Industry
Pharmaceutical Preparations
Location
2656 State Street, Carlsbad, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.22K % +20.4%
Debt-to-equity 4.76 % -21.7%
Return On Equity -23.5 % +22.3%
Return On Assets -22.4 % +21.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.1M shares +1.08%
Common Stock, Shares, Outstanding 50.7M shares +18%
Entity Public Float 338M USD +26.3%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 57.2M shares +34%
Weighted Average Number of Shares Outstanding, Diluted 57.2M shares +34%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 80.1M USD +28.1%
General and Administrative Expense 24.1M USD +38.3%
Operating Income (Loss) -104M USD -30.3%
Nonoperating Income (Expense) 17.7M USD +63.7%
Net Income (Loss) Attributable to Parent -86.5M USD -25.1%
Earnings Per Share, Basic -1.51 USD/shares +6.79%
Earnings Per Share, Diluted -1.51 USD/shares +6.79%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 92M USD +58.5%
Assets, Current 347M USD +64.2%
Property, Plant and Equipment, Net 1.65M USD +1.41%
Other Assets, Noncurrent 7.38M USD +46.6%
Assets 364M USD +61%
Accounts Payable, Current 590K USD -87.3%
Liabilities, Current 14.6M USD -4.82%
Operating Lease, Liability, Noncurrent 5.81M USD -6.53%
Other Liabilities, Noncurrent 3K USD -93.5%
Liabilities 20.4M USD -5.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 770K USD +102%
Retained Earnings (Accumulated Deficit) -251M USD -52.5%
Stockholders' Equity Attributable to Parent 343M USD +68%
Liabilities and Equity 364M USD +61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22M USD -124%
Net Cash Provided by (Used in) Financing Activities 200M USD +53175%
Net Cash Provided by (Used in) Investing Activities 18.1M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 50.8M shares +17.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 196M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 93M USD +57.6%
Deferred Tax Assets, Valuation Allowance 63.3M USD +54.6%
Deferred Tax Assets, Gross 64.8M USD +52.3%
Operating Lease, Liability 6.22M USD -4.22%
Depreciation 500K USD +25%
Payments to Acquire Property, Plant, and Equipment 136K USD +232%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -86.1M USD -25.2%
Lessee, Operating Lease, Liability, to be Paid 8.69M USD -8.08%
Property, Plant and Equipment, Gross 2.93M USD +20.4%
Operating Lease, Liability, Current 412K USD +47.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 900K USD +3.09%
Lessee, Operating Lease, Liability, to be Paid, Year One 874K USD +13.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.47M USD -16.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 927K USD +3.12%
Deferred Tax Assets, Operating Loss Carryforwards 18.9M USD +34.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 5.53M USD +83.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 955K USD +3.13%
Operating Lease, Payments 800K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 122K USD +47%
Deferred Tax Assets, Net of Valuation Allowance 1.54M USD -6.33%
Share-based Payment Arrangement, Expense 22.8M USD +68.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%